Research Article
Effect of COVID-19 Pandemic-Related Delays in Chemoembolization on the Survival of Patients with Hepatocellular Carcinoma
Table 2
Patient and tumor characteristics of the study participants who underwent repeated TACE.
| | Factors | Value |
| | Patients (n) | 145 | | Age, years, mean ± SD | 64.0 ± 9.7 | | Sex, male (%) | 109 (75) | | Liver disease etiology (%) | | HBV/HCV/HBV + HCV/alcohol/others | 55/24/2/6/13 | | Child–Pugh classification (%) | | A/B | 78/22 | | BCLC stage (%) | | A/B/C | 14/73/13 | | AFP (ng/mL), % | | ≤200/>200 | 70/30 | | ALT (U/L), median (IQR) | 32.0 (23.0–43.0) | | AST (U/L), median (IQR) | 49.0 (34.0–76.0) | | Total bilirubin (mg/dL), median (IQR) | 0.8 (0.5–1.3) | | Albumin (g/dL), mean ± SD | 3.5 ± 0.6 | | Platelet count (×103/mm3), median (IQR) | 103.0 (71.0–153.0) | | Size of main tumor (cm), median (range) | 3.0 (1.1–16.0) | | Number of tumors (%) | | 1–3/4-5/>5 | 55/19/26 | | Presence of vascular invasion, n (%) | 15 (10) | | Previous TACE sessions, median (range) | 2 (1–13) | | Time interval (days), mean ± SD | 68.9 ± 29.3 | | Hospitalization (days), median (range) | 3 (2–40) |
|
|
TACE, transarterial chemoembolization; SD, standard deviation; HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; ALT, alanine transaminase; IQR, interquartile range; AST, aspartate transaminase.
|
